

Metformin prevents metabolic side effects during systemic glucocorticoid treatment.

Seelig E, et al. Eur J Endocrinol. 2017; 176(3): 349-358.

- Patients receiving glucocorticoid treatment are prone to develop metabolic complications.
- In a randomised controlled trial of metformin targeting metabolic complications in **non-diabetic patients** needing glucocorticoid (prednisone, prednisolone or methylprednisolone) therapy, metformin (850 mg once daily for one week followed by 850 mg twice daily for three weeks) exerted a beneficial effect on glycaemic control.

Metformin seems to be a promising drug for preventing metabolic side effects during systemic glucocorticoid treatment.